Ticagrelor Tablet
Product Images NDC 50268-826

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 50268-826). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (826 01)

Description: The text is a product label for Ticagrelor Tablets. The label provides information on the dosage, active ingredient content, storage instructions, and manufacturing details. The tablets contain 90mg of ticagrelor and are intended for adult use. It is recommended to dispense the accompanying Medication Guide to each patient. The storage temperature is specified as 25°C (77°F) with excursions permitted between 15-30°C (59-86°F). The tablets are produced by AVKARE/AVPAK in Pulaski, Tennessee and by SN Laboratories in Telangana, India. The label also includes a Manufacture License Number and Revision Information. Note: may cause errors in the content.*

FDA Label Image

Tica-tabs-fig-01 (Tica Tabs Fig 01)

FDA Label Image

Tica-tabs-fig-02 (Tica Tabs Fig 02)

FDA Label Image

Tica-tabs-fig-03 (Tica Tabs Fig 03)

FDA Label Image

Tica-tabs-fig-04 (Tica Tabs Fig 04)

FDA Label Image

Tica-tabs-fig-05 (Tica Tabs Fig 05)

FDA Label Image

Tica-tabs-fig-06 (Tica Tabs Fig 06)

FDA Label Image

Tica-tabs-fig-07 (Tica Tabs Fig 07)

FDA Label Image

Tica-tabs-fig-08 (Tica Tabs Fig 08)

This text provides medication recommendations based on the effects of various inhibitors and inducers on CYP3A4 enzymes. It includes information on avoiding concomitant use of certain strong CYP3A4 inhibitors like Ketoconazole, making no dose adjustments for moderate CYP3A4 inhibitors such as Diltiazem, and avoiding concomitant use of potent CYP3A4 inducers like Rifampin. It also mentions drugs where no dose adjustments are needed when combined with P-gP and CYP3A inhibitors. Specific dosing instructions are highlighted for drugs like Desmopressin, Heparin, and Enoxaparin. Overall, this document is useful for healthcare professionals managing patients taking multiple medications that interact with CYP3A4 enzymes.*

FDA Label Image

Tica-tabs-fig-09 (Tica Tabs Fig 09)

This text provides information on drug interactions with Ticagrelor, including recommended dose adjustments for various medications when used in combination with Ticagrelor. It outlines specific dosage recommendations for Ticagrelor in combination with drugs such as Simvastatin, Atorvastatin, Lovonorgestrel, Etinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. The text helps healthcare professionals make informed decisions when prescribing these medications concurrently with Ticagrelor.*

FDA Label Image

Tica-tabs-fig-10 (Tica Tabs Fig 10)

FDA Label Image

Tica-tabs-fig-11 (Tica Tabs Fig 11)

FDA Label Image

Tica-tabs-fig-12 (Tica Tabs Fig 12)

FDA Label Image

Tica-tabs-fig-13 (Tica Tabs Fig 13)

FDA Label Image

Tica-tabs-fig-14 (Tica Tabs Fig 14)

Not available.*

FDA Label Image

Tica-tabs-fig-15 (Tica Tabs Fig 15)

FDA Label Image

Tica-tabs-fig-16 (Tica Tabs Fig 16)

FDA Label Image

Tica-tabs-fig-17 (Tica Tabs Fig 17)

FDA Label Image

Tica-tabs-fig-18 (Tica Tabs Fig 18)

This data provides detailed information on the characteristics of patients included in a study, including age distribution, sex ratio, race, weight, BMI, geographic region, medical history related to stroke, TIA, diabetes, hypertension, prior ischemic events, smoking status, as well as the results of the study, comparing the use of Ticagrelor and Placebo. The information is presented in numerical values and percentages, with HR (95% CI) values included for different factors. This data could be valuable for analyzing the demographics and outcomes of a clinical trial or research study.*

FDA Label Image

Tica-tabs-structure (Tica Tabs Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.